141W94 - Feb., p. 42; June, p. 131; July, p. 169; Sep., p. 230
1592U89 - July, p. 168; Oct., p. 272; Nov., p. 299
2',3'-dideoxycytidine (use DDC)
2',3'-dideoxyinosine (use DDI)
3TC - Mar., p. 70; May, p. 107; June, p. 138, 142; July, p. 172; Aug., p. 193, 202, 205; Nov., p. 296
5-fluorouracil - Mar., p. 74; June, p. 132
A7-183 - Sep., p. 234
AccuSite Injectable Gel - Mar., p. 74; June, p. 132
acyclovir - May, p. 107; Aug., p. 200; Oct., p. 264
acyclovir phosphate, di[methyl-3-hydroxy-3-(1-acetoxyphenyl)propanoate] - Sep., p. 234
adefovir dipivoxil - Sep., p. 226
adenine, (R)-9-(2-phosphonylmethoxypropyl) [use PMPA]
adenovirus vectors - Apr., p. 108
Adjumer adjuvants - Nov., p. 293
Advantage 24 - June, p. 137
AG1343 (use nelfinavir mesylate)
Alferon (use interferon-alfa-n3)
allophenylnorstatine - July, p. 172
Alpha Leukoferon - May, p. 106
ALVAC-HIV (vCP205) - Aug., p. 203
amantadine - Aug., p. 199; Nov., p. 300
AmpErase - June, p. 129
Amplicor HIV-1 Monitor - June, p. 129
Ampligen - June, p. 136
AndroVir - Dec., p. 323
Anti-CD4-Clone - Aug., p. 202
antisense, gene therapy - Apr., p. 107
antisense oligonucleotides - Aug., p. 202; Oct., p. 266, 267
antisense oligonucleotides, HIV - Apr., p. 103
antisense oligonucleotides, phosphorothioates - Aug., p. 195
AR177 - May, p. 107; Oct., p. 265; Nov., p. 298
Aspidos - June, p. 138
AzddMeC - May, p. 108
AZT - Feb., p. 42; Mar., p. 70; May, p. 107; June, p. 136; July, p. 167, 170, 171; Aug., p. 193; Sep., p. 233; Nov., p. 296, 301; Dec., p. 326, 327
AZT, generic - Feb., p. 43
AZT prodrugs - May, p. 108
Aztec (AZT, controlled release) - July, p. 170
BB-10010 - Nov., p. 298
BCH-189 (use 3TC and lamivudine)
benzimidazole ribosides - Nov., p. 293
bile acids, topical - Oct., p. 267
Bio-Hep-B - Oct., p. 270
Bioadhesive Delivery System - June, p. 137
BioLogic-HT System - Oct., p. 267
bis(POM)PMEA - Feb., p. 39
bovine immunodeficiency virus vaccines - Nov., p. 296
boxwood tree - Aug., p. 197
Buxus sempervivens - Aug., p. 197
BV-araU - June, p. 139
calcium response modifiers - Aug., p. 206
carbovir compounds - Oct., p. 272; Nov., p. 299
carboxyamidotriazole - Aug., p. 206
CC-CKR-5 (CCR-5) - July, p. 165; Aug., p. 194
CCR-5 receptor inhibitors - Dec., p. 330
chemokine receptor inhibitors - Dec., p. 330
chemokines - July, p. 165; Aug., p. 194, 206; Oct., p. 269; Nov., p. 298; Dec., p. 330
cholic acid - Oct., p. 267
cidofovir, injection - Mar., p. 74; May, p. 104; July, p. 161; Aug., p. 195; Oct., p. 271
cidofovir, prodrug - Feb., p. 41
cidofovir, topical - Feb., p. 39, 41; May, p. 103; June, p. 137
cimetidine - Dec., p. 332
CMV antibody, humanized - Oct., p. 261
CMV antisense oligonucleotides - Oct., p. 266
CMV plasma viral load - Aug., p. 197
CMV protease - Oct., p. 270
CMV vaccines - Aug., p. 200; Dec., p. 325
Comvax - Nov., p. 301
Confide - June, p. 139
Crixivan (use indinavir sulfate)
CS-92 - May, p. 108
Curcuma zedoria - Oct., p. 268
curcumin - Apr., p. 105
cyclic ureas - Apr., p. 101
CytoGam - May, p. 105
cytokine combinations - June, p. 136
Cytolin - Dec., p. 334
Cytomegalovirus Immune Globulin Intravenous - Aug., p. 200
cytotoxic T lymphocytes - May, p. 104
D-125 - Apr., p. 104
D4T - Feb., p. 34; Mar., p. 72, 74; June, p. 137
DAPD - May, p. 108
daunorubicin, liposomal - May, p. 107
DaunoXome - May, p. 107
DC-Cholesterol cationic lipids - Mar., p. 79
DDC - Mar., p. 70; May, p. 97; Nov., p. 296
DDI - Mar., p. 68, 72; Apr., p. 102; May, p. 107; June, p. 139; Nov., p. 296; Dec., p. 326
delavirdine mesylate - Feb., p. 38; Apr., p. 105; Aug., p. 203; Nov., p. 300; Dec., p. 332
dihydropyrones - July, p. 172
diphenylhexane, 2,5-diamino-3,4-Disubstituted-1,6- - Aug., p. 206
disinfectants - Apr., p. 104
DMP 266 - Sep., p. 231
DMP 450 - Apr., p. 101
DNA plasmid vaccines, HIV - May, p. 103
docosanol (use Lidakol)
Engerix-B - May, p. 109; Oct., p. 270
Epivir (use 3TC)
Epstein-Barr virus subunit vaccines - Feb., p. 44
External Guide Sequence (EGS) - Aug., p. 201; Dec., p. 331
F-ddA, beta- - June, p. 133
famciclovir - Mar., p. 73; Sep., p. 228, 235; Oct., p. 264; Nov., p. 289
Famvir (use famciclovir)
Ferimmune - May, p. 101
fialuridine (FIAU) - Nov., p. 297
fluorescent electrophoresis-based DNA analysis - Sep., p. 238
fluoroadenosine, 2',3'-dideoxy-2'-beta- - June, p. 133
Fluvirin - May, p. 107
fomivirsen - Aug., p. 195; Oct., p. 267
foscarnet - Feb., p. 40; May, p. 106
(-)-FTC - May, p. 108
fungal extracts - Aug., p. 201
fusin - May, p. 98; Sep., p. 235
ganciclovir - Feb., p. 40; May, p. 106; Sep., p. 233
ganciclovir, ocular implant - Mar., p. 66
ganciclovir, oral - Feb., p. 41; Sep., p. 229; Dec., p. 322
Geissospermum vellosii - June, p. 138
GEM 91 - Apr., p. 103; Oct., p. 266
GEM 132 - Aug., p. 196; Oct., p. 266
gene therapy, antisense - June, p. 134
gene therapy, DNA vaccines - May, p. 105
gene therapy, ex vivo - Feb., p. 41
gene therapy, hepatitis B - Mar., p. 72
gene therapy, HIV - Apr., p. 101, 102; May, p. 103; Dec., p. 327
gene therapy, HSV thymidine kinase gene - Dec., p. 335
gene therapy, retroviral vectors - Mar., p. 78
genetic protection, HIV - Aug., p. 194
GENEVAX-HIV - May, p. 103
GG167 - Apr., p. 104
GS 4104 - Sep., p. 231
GS 504, topical - Feb., p. 39
GS 840 - Feb., p. 39; Sep., p. 226
GS 930 - Feb., p. 41
guanine, 9-(4-hydroxy-3-hydroxymethylbut-1-yl)- (use penciclovir)
H-BIG - Sep., p. 235
Havrix (use Hepatitis A Vaccine, Inactivated)
HCV - Aug., p. 200
HCV NS3 protease - Oct., p. 263
Hepatitis A Vaccine, Inactivated - Apr., p. 98, 104; Sep., p. 232
hepatitis A/B vaccines - Dec., p. 331
hepatitis B antibodies, human - Dec., p. 328
Hepatitis B Immune Globulin [Human] - Sep., p. 235
hepatitis B vaccines - Feb., p. 45; May, p. 109; June, p. 132; Oct., p. 270; Nov., p. 301; Dec., p. 330
hepatitis C virus genome - Apr., p. 107
Heptavax-B - Nov., p. 301
HGP-30 - June, p. 141; July, p. 168; Nov., p. 297
HIV antisense oligonucleotides - Oct., p. 266
HIV aspartyl proteases - Aug., p. 206
HIV eradication - Aug., p. 198
HIV gene therapy - Apr., p. 101, 102; May, p. 103; Dec., p. 327
HIV gp120 vaccines - Mar., p. 68, 74; Apr., p. 103; Aug., p. 203; Oct., p. 269
HIV gp160 vaccines - Apr., p. 100; May, p. 102; Sep., p. 234
HIV immune globulin - Aug., p. 203
HIV-infection co-factors - May, p. 98; July, p. 165; Sep., p. 235
HIV integrase inhibitors - May, p. 107; Oct., p. 265; Nov., p. 298
HIV LTR inhibitors - Aug., p. 206
HIV monoclonal antibodies - Aug., p. 202
HIV p17 vaccines - June, p. 141; July, p. 168; Nov., p. 297
HIV p17/p24:Ty-VLP vaccines - May, p. 106
HIV polypeptides - Apr., p. 107; Nov., p. 294
HIV protease inhibitors - Feb., p. 36, 37, 40, 42; Mar., p. 65, 72, 73, 74; Apr., p. 97; May, p. 99, 104; June, p. 136, 137, 138; July, p. 164, 169, 172; Aug., p. 203, 206; Sep., p. 230, 233; Nov., p. 296, 297, 298
HIV protein-tyrosine kinase inhibitors - Dec., p. 323
HIV research reagents - June, p. 141
HIV rev M10 gene therapy- Apr., p. 102; Dec., p. 327
HIV reverse transcriptase inhibitors - May, p. 108
HIV transframe peptide inhibitors - Aug., p. 206
HIV vaccines - Mar., p. 76, 77; May, p. 103; Aug., p. 201; Dec., p. 330, 333
HIV vaccines, beta2-microglobulin - June, p. 141
HIV vaccines, canarypox vectors - Mar., p. 74; Aug., p. 203
HIV viral load, lymphatic - Nov., p. 292, 294
HIV viral load, plasma - Feb., p. 35, 38; June, p. 129, 131, 136; July, p. 164
HIV-1 g41 immunotherapeutic antibody - Apr., p. 102
HIV-1 inactivated core vaccine (use Remune)
HIV-1 p24 Antigen ELISA Test System - June, p. 139
HIV-1 Urine EIA - Aug., p. 203
HIV-1 Western Blot diagnostics - Feb., p. 45
Hivid (use DDC)
HIVIG - Aug., p. 203
HNK20 - May, p. 103; Aug., p. 199
homeopathic drugs - Feb., p. 45
HPMPC (use cidofovir)
herpes simplex virus-1 thymidine kinase genes - Sep., p. 233
herpes simplex virus vaccines - July, p. 170; Sep., p. 227, 232; Nov., p. 297; Dec., p. 325, 329
herpesvirus entry mediator (HVEM) - Nov., p. 299
Human Anti-Hepatitis B Antibody - Dec., p. 328
human growth hormone - Sep., p. 236
human leukocyte antigens - June, p. 135
human papillomavirus vaccines - Feb., p. 45; June, p. 133, 137; July, p. 170, 174; Dec., p. 324
hydrocortisone - Oct., p. 268
hydroxyurea - Apr., p. 102
hypericin - Oct., p. 268
hyperthermia, whole-body - Oct., p. 267
inactivated poliovirus vaccine (IPV) - Sep., p. 235
indinavir sulfate - Feb., p. 37; Apr., p. 97; May, p. 99; July, p. 172; Aug., p. 203; Sep., p. 231; Nov., p. 296, 297, 298, 299
Infergen (use interferon, consensus)
influenza vaccines - Apr., p. 100; May, p. 107; Sep., p. 232; Oct., p. 260; Nov., p. 293; Dec., p. 332
InnoPhor drug delivery - Aug., p. 201
interferon, alfa-n1 - May, p. 101
interferon, alfa-n3 - May, p. 101, 105; Aug., p. 200
interferon, alpha - Feb., p. 44; May, p. 106, 109; July, p. 167
interferon, alpha-2a - Sep., p. 234; Dec., p. 321
interferon, alpha-2b - May, p. 109; Nov., p. 291
interferon, consensus - June, p. 141; Dec., p. 335
interferon, gamma-1b- - June, p. 136
interferon, polyethylene glycolated-alpha - Nov., p. 302
interleukin-2 - June, p. 136; July, p. 166; Oct., p. 257
interleukin-2, polyethylene glycolated - July, p. 166
interleukin-10 (IL-10) - Nov., p. 298
interleukin-12 (IL-12) - Nov., p. 297
Intron A (use interferon, alpha-2b-)
Invirase (use saquinavir)
IOT4a - Aug., p. 202
ISIS 2922 (use fomivirsen)
kynostatin (KNI-272) - July, p. 172
lactoglobulin, 3-hydroxyphthalic anhydride bovine beta- - May, p. 106
lamivudine - June, p. 142; Nov., p. 290
Lidakol - Feb., p. 44; Apr., p. 104; Aug., p. 200; Dec., p. 335
lipid conjugates, foscarnet - June, p. 135
lipid conjugates, HIV nucleosides - June, p. 135
Liposome-CD4 - June, p. 141
lymphocyte LFA-1 antibodies - Dec., p. 334
lymphocyte transfer, allogeneic - Aug., p. 203
macrophage inflammatory protein 1alpha (MIP-1a) - Nov., p. 298
macrophage inflammatory protein 1beta (MIP-1b) - Aug., p. 206
MDX-240 - Apr., p. 102
MEDI-493 - Dec., p. 325
methylcytidine, 3'-azido-2',3'-dideoxy-5- - May, p. 108
MF-59 adjuvants - Sep., p. 227
Micromer microsphere vaccines - Nov., p. 293
milk proteins - May, p. 106
MKC-422 - Feb., p. 39; May, p. 108
MMS1 - June, p. 136
monophosphoryl lipid A - Feb., p. 45
mucosal immunity - Nov., p. 300
music, soothing - Nov., p. 300
n-docosanol (use Lidakol)
nelfinavir mesylate - Feb., p. 40; Mar., p. 74; June, p. 137; July, p. 164; Sep., p. 234; Nov., p. 295, 298; Dec., p. 331
neuraminidase inhibitors - Sep., p. 231
nevirapine - Mar., p. 71; May, p. 107; July, p. 163; Aug., p. 200; Dec., p. 326
non-nucleoside reverse transcriptase inhibitors, HIV - Apr., p. 105; May, p. 107, 108; July, p. 163; Aug., p. 200, 203; Sep., p. 231; Nov., p. 300; Dec., p. 326, 332
nonoxynol-9 - June, p. 137
Norvir (use ritonavir)
nucleic acid sequence based amplification - June, p. 129
nucleotide analogs, acyclic - Oct., p. 263
oligonucleotides, guanine-thymine - Oct., p. 265
Oral Polio Vaccine (OPV) - Sep., p. 235
OraSure HIV-1 Western Blot Kit - June, p. 139
OST 577 - Dec., p. 328
oxathiolanes, substituted 1,3- - June, p. 142
Oxoferin - Oct., p. 262
parvovirus B19 vaccines - June, p. 142
penciclovir cream - Sep., p. 225; Oct., p. 270
peptidoglycans, fungal - June, p. 136
Perthon/Abavca - Oct., p. 268
plant-derived drugs - Feb., p. 45; June, p. 138; Aug., p. 197; Oct., p. 268; Dec., p. 323
pleconaril - Oct., p. 269
PMPA - June, p. 133; Oct., p. 263
PN355 - Dec., p. 323
podophyllotoxin - Nov., p. 297
poliovirus vaccines - Dec., p. 329
poly[di(carboxylatophenoxy)phosphazene] - Nov., p. 293
poly I:poly (C12U) - June, p. 136
polymerase chain reaction (PCR) - June, p. 129; Aug., p. 205
pomegranate extracts - Apr., p. 104
progesterone - June, p. 137
Proleukin (use interleukin-2)
protease inhibitors, unspecified - Sep., p. 234
Protovir - Oct., p. 261
Public Places spray - Apr., p. 104
QS-21 Stimulon vaccine adjuvants - Aug., p. 202
Quantiplex HIV RNA assays - June, p. 129, 136
rabies vaccines - Sep., p. 232
RANTES - Aug., p. 206; Oct., p. 269
Remune - Apr., p. 105; May, p. 104; Aug., p. 203; Oct., p. 268; Nov., p. 296, 298
Rescriptor (use delavirdine)
RespiGam (use Respiratory Syncytial Virus Immune Globulin)
respiratory syncytial virus antibodies - May, p. 103; Aug., p. 199; Dec., p. 325
Respiratory Syncytial Virus Immune Globulin - Feb., p. 33; Mar., p. 72; May, p. 105; Aug., p. 200
Reticulose - June, p. 138; Oct., p. 268; Dec., p. 331
Retrovir (use AZT)
ribavirin - Sep., p. 236; Oct., p. 269
ribosomal frameshifting - July, p. 173
ribozymes - Feb., p. 41; Apr., p. 108; June, p. 138, 140; Aug., p. 201; Dec., p. 331
rifamycins - Nov., p. 296
RILONs - June, p. 138; Dec., p. 331
ritonavir - Feb., p. 36; Mar., p. 65, 72, 74; May, p. 104, 107; July, p. 169; Aug., p. 203; Sep., p. 235; Nov., p. 292, 297
Roferon A (use interferon, alpha-2a-)
rotavirus vaccines, live oral - Oct., p. 266
Salk HIV vaccine (use Remune)
saquinavir - Mar., p. 73, 74; May, p. 97, 104; Aug., p. 203; Sep., p. 230; Nov., p. 295, 297, 298
Sentinel HIV-1 Urine EIA - Aug., p. 203
Serostim - Sep., p. 236
Sindbis virus vectors - June, p. 134
somatropin - Sep., p. 236
sorivudine - June, p. 139
SPV-30 - Aug., p. 197
stavudine - Feb., p. 34
steroids - Oct., p. 268
stromal cell-derived factor I (SDF-1) - Sep., p. 235
surfactants, pulmonary - Oct., p. 267
Symmetrel - Aug., p. 199; Nov., p. 300
TA-GW - July, p. 170; Dec., p. 324
TA-HPV - Feb., p. 45; June, p. 133
Tagamet - Dec., p. 332
Taq DNA polymerase - Aug., p. 205; Nov., p. 302
T-cell activation drugs - Apr., p. 106
T-cell Modulation Process - June, p. 141
tetanus vaccines - May, p. 102
tetrachlorodecaoxygen - Oct., p. 262
Theradigm-HBV - June, p. 132; Dec., p. 330
thiacytidine, (-)2',3'-dideoxy-3'- (use 3TC)
thiacytidine, (-)-2',3'-dideoxy-5-fluoro-3'- - May, p. 108
thymine, (+)-L-b-dioxolane- - May, p. 108
thymosin alpha 1 - Apr., p. 104; July, p. 167; Aug., p. 194; Sep., p. 229; Oct., p. 264; Nov., p. 291, 302
translation inhibitors - July, p. 173
Trimera technology - Nov., p. 300
tumor necrosis factor/nerve growth factor receptors - Nov., p. 299
Twinrix - Dec., p. 331
U-10317 - July, p. 172
U-140690 - July, p. 172
uracil, (E)-5-(2-bromovinyl)arabinofuranosyl- (use sorivudine)
Usevir - June, p. 139
vaccine adjuvants - Mar., p. 79; June, p. 141
vaccines, general - Mar., p. 73
valacyclovir - May, p. 107; Oct., p. 264
Valtrex (use valacyclovir)
Vaqta - Apr., p. 98
VaxSyn HIV-1 - Apr., p. 100; May, p. 102
Vectavir (use penciclovir)
Videx (use DDI)
VIMRxyn - Oct., p. 268
Viracept (use nelfinavir mesylate)
Viramune (use nevirapine)
Virazole - Sep., p. 236
virucides - Apr., p. 104; May, p. 106; June, p. 133; Oct., p. 262, 267
virus-like particle vaccines - May, p. 106
Vistide (use cidofovir)
Vitrasert Implant - Mar., p. 66
VP 63843 - May, p. 102; Oct., p. 269
VX-478 (use 141W94)
WF10 - Oct., p. 262
Zadaxin (use thymosin alpha 1)
Zerit (use D4T)
Zovirax (use acyclovir)